Evaluation of Safety, efficacy, and QOL with Glecaprevir and Pibrentasvir therapy in Dialysis Patients Infected with Hepatitis C Virus

Evaluation of Safety, efficacy, and QOL with Glecaprevir and Pibrentasvir therapy in Dialysis Patients Infected with Hepatitis C Virus - Evaluation of Safety, efficacy, and QOL with Glecaprevir and Pibrentasvir therapy in Dialysis Patients Infected with Hepatitis C Virus

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030229

Enrollment

Registered

2017-12-04

Start date

2017-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis-C, Chronic Renal failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Depends on insurance adaptation

Exclusion criteria

Exclusion criteria: Depends on insurance adaptation

Design outcomes

Primary

Measure	Time frame
Sustained Virological Response at 12weeks after treatment	—

Secondary

Measure	Time frame
Safety and QOL during 6 months after treatment, and the period of treatment	—

Countries

Japan

Contacts

Public ContactMikio Sato

Kasama Chuo Clinic Internal medicine

hmsato@mail1.accsnet.ne.jp0296-71-6001

Outcome results